Danny Kharazmi
Admitted to the Ontario Bar: 2014
-
Toronto
- Bio
- Awards & Recognition
- Professional Involvement
- Representative Matters
- Selected Publications
- Insights
- Education
Danny thrives on finding effective and creative solutions to help clients navigate through highly regulated industries. By carefully considering the needs and goals of his clients, he provides an array of value-added solutions in relation to securities and corporate law matters.
Danny is a member of the firm’s Capital Markets, Corporate/Commercial and Mergers & Acquisitions Groups. He has expertise in a broad range of transactions and has led complex going public transactions and mergers and acquisitions. Danny is a trusted advisor to public and private companies, guiding them through all aspects of the startup phase, going public and transformational transactions. He also regularly advises members of senior management and boards of directors on continuous disclosure obligations and corporate governance matters.
Danny advises both public and private issuers in a broad range of industries, including biotech, esports, Fintech, mining and cannabis.
Danny is also an adjunct professor at Osgoode Hall Law School.
Awards & Recognition
- Recognized in Best Lawyers: Ones to Watch in Canada in Securities Law
- Recognized in the Global Top 200 Psychedelics Lawyers Directory 2022 – 2025
Professional Involvement
Professional Activities
- Board Member, Herbert H. Carnegie Future Aces Foundation
Membership
- Law Society of Ontario
Representative Matters
Represented a Canadian fintech company in the completion of its concurrent private placement financing and acquisition of the assets of a French fintech company.
Represented Cybin Inc. (CBOE: CYBN) (NYSE American: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, in the completion of a US$150-million private placement of common shares.
Represented Cybin Inc. (NEO:CYBN) (NYSE American: CYBN), a life sciences company focused on psychedelic pharmaceutical therapies, in the completion of its US$30 million underwritten public offering of units.
Represented Cybin Inc., a life sciences company focused on psychedelic pharmaceutical therapies, in the completion of a US$30 million common share purchase agreement.
Represented Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, in the completion of an overnight marketed offering pursuant to a prospectus supplement to Cybin's short form base shelf prospectus, with aggregate gross proceeds of approximately $34 million.
Represented Small Pharma Ltd, a U.K.-based neuropharmaceutical company specialized in IP-led development of novel treatments for mental health conditions, in its acquisition by Small Pharma Inc. (formerly Unilock Capital Corp.) (TSXV: DMT) by way of a qualifying transaction and its related brokered and non-brokered private placements for aggregate gross proceeds of $63 million and initial TSX Venture Exchange listing.
Represented Cybin Inc., a biotechnology company focused on progressing psychedelic therapeutics, in the completion of a bought deal short form prospectus offering of units for aggregate gross proceeds of approximately $34 million.
Represented Cybin Inc. (the “Company”) (NEO: CYBN) in the completion of its reverse takeover of Clarmin Explorations Inc. pursuant to the terms of an amalgamation agreement among Cybin Corp., Clarmin and a wholly-owned subsidiary of the Company as well as a private placement offering of 60 million subscription receipts for aggregate gross proceeds of $45 million.
Selected Publications
Co-Author, "A New Era for the CSE: What Issuers Need to Know," Aird & Berlis LLP, May 2, 2023.
"Legal and Regulatory Landscape for Psychedelics Companies Considering Going Public in Canada," Aird & Berlis LLP's Capital Markets Newsletter, July 8, 2020.
Insights
Education
- JD, University of Ottawa, 2013
- MBA, University of Ottawa, 2013
- MPA, Queen's University, 2006
- BA (Honours), University of Toronto, 2005